

Product Data Sheet

TGFBR2/TGF-beta RII Protein, Human (HEK293, Fc)

Cat. No.:	HY-P7426
Synonyms:	TGFR-2; TGF-beta type II receptor; TGF-beta receptor type 2; TbetaR-II
Species:	Human
Source:	HEK293
Accession:	P37173 (T23-D159)
Gene ID:	7048
Molecular Weight:	Approximately 55-75 kDa

PROPERTIES	
PROPERTIES	
AA Sequence	TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
Biological Activity	Measured by its ability to inhibit TGF-beta 1 activity on HT-2 mouse T cells. The ED ₅₀ this effect is 3.527 μg/mL in the presence of 0.25 ng/mL of recombinant human TGF-beta 1, corresponding to a specific activity is 283.527 units/mg.
Appearance	Lyophilized powder.
Formulation	Lyophilized after extensive dialysis against 20 mM PB, 150 mM NaCl, pH 7.4 or PBS, pH 7.4.
Endotoxin Level	<1 EU/µg, determined by LAL method.
Reconsititution	It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH ₂ O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background

Transforming growth factor-beta receptor type 2 (TβRII) is a 567 amino acid single-pass type I membrane protein that contains one protein kinase domain. TβRII is the specific receptor for TGFβ ligands, and crucial for the regulation of TGFβ signaling in tumor initiation, progression, and metastasis^[1]. T beta R-II (transforming growth factor beta [TGF-beta] type II receptor) is a transmembrane serine/threonine kinase that acts as the primary TGF-beta receptor. Ligand binding to T beta R-II leads to the recruitment and phosphorylation of T beta R-I, a distantly related transmembrane kinase that acts as a

REFERENCES

[1]. Gao N, et al. Clinical Implications of TβRII Expression in Breast Cancer. PLoS One. 2015 Nov 9;10(11):e0141412.

[2]. Cárcamo J, et al. Disruption of transforming growth factor beta signaling by a mutation that preventstransphosphorylation within the receptor complex. Mol Cell Biol. 1995 Mar;15(3):1573-81.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA